Clinical research has been an important component of McLean’s Alcohol and Drug Abuse Treatment Program (ADATP) for more than thirty years. Our researchers develop and test new treatments for specific groups of patients who have substance use disorders.
Roger Weiss, MD, and colleagues have developed an evidence-based group treatment for patients with co-occurring substance use disorders and bipolar disorder. Integrated Group Therapy (IGT) was named one of only five “examples of promising behavioral therapies for adult patients with co-occurring conditions” in a National Institute on Drug Abuse research report.
Our research projects include new treatments for cannabis dependence (Dr. Kevin Hill) and for substance use disorders with co-occurring anxiety (Dr. R. Kathryn McHugh).
ADATP researchers have played a leading role in the National Institute on Drug Abuse Clinical Trials Network, a partnership between addiction research centers and community drug abuse treatment programs. Dr. Weiss recently led a multi-site study of the treatment for prescription opioid dependence. The ADATP incorporates findings from these studies and delivers cutting edge, evidence-based treatments.